NNBXF Nanobiotix S.A.

Price Chart

Executive Summary

Nanobiotix filed a 6-K concurrently with a massive ~155% dilutive offering (75M shares/ADSs/pre-funded warrants via 424B5). The filing provides a business update including promising but early (n=7) Phase 2 CONVERGE data in NSCLC with 85.7% ORR, a NANORAY-312 protocol amendment eliminating the interim analysis and accelerating the final readout, and Curadigm preclinical updates. The dominant event is the offering's substantial dilution, which overwhelms the positive clinical signals.

Actionable Insight

Key Facts

• Filed concurrently with 424B5 offering of up to 75,000,000 ordinary shares/ADSs/pre-funded warrants (~155% dilution of current shares outstanding)
• CONVERGE Phase 2 NSCLC data (n=7): 85.7% ORR, 57.1% CRR, 100% DCR post-chemoradiation + durvalumab
• NANORAY-312 protocol amendment eliminates interim analysis (283 events), final analysis now at 335 events with 92% power
• Up to ~$200 million in aggregate J&J milestone payments eligible over next few years across H&N and lung programs
• Curadigm platform: early-stage preclinical data, IND readiness package underway

Financial Impact

Massive dilution: offering of up to 75M shares at undisclosed price, representing ~155% of current shares outstanding. Proceeds will fund pipeline acceleration but greatly exceed existing market cap.

Risk Factors

• Catastrophic dilution from 75M share offering overwhelms any positive clinical catalyst in the near term
• Pre-revenue stage with no approved products; cash burn remains high
• Early clinical data (n=7) may not replicate in larger randomized Part 2 of CONVERGE
• J&J milestone payments are contingent on development/regulatory events that may not occur on schedule

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status

Related Tickers